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Aims: The prognosis of patients with pancreatic cancer has remained virtually unchanged with a high
mortality rate compared to other types of cancers. An earlier detection would provide a time window of
opportunity for treatment and prevention of deaths.
In the present study we investigated extracellular vesicle (EV)-associated potential biomarkers for
pancreatic cancer by directly assessing EV size-based subpopulations in pancreatic juice samples of
patients with chronic pancreatitis or pancreatic cancer. In addition, we also studied blood plasma and
pancreatic cancer cell line-derived EVs.
Methods: Comparative proteomic analysis was performed of 102 EV preparations from human pancreatic
juices, blood, and pancreatic cancer cell lines Capan-1 and MIA PaCa-2. EV preparations were also
characterized by electron microscopy, tunable resistive pulse sensing, and ﬂow cytometry.
Results: Here we describe the presence of EVs in human pancreatic juice samples. Pancreatic juice EV-
associated proteins that we identiﬁed as possible candidate markers for pancreatic cancer included
mucins, such as MUC1, MUC4, MUC5AC, MUC6 and MUC16, CFTR, and MDR1 proteins. These candidate
biomarkers could also be detected by ﬂow cytometry in EVs found in pancreatic juice and those secreted
by pancreatic cancer cell lines.
Conclusions: Together our data show that detection and characterization of EVs directly in pancreatic
juice is feasible and may prove to be a valuable source of potential biomarkers of pancreatic cancer.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Globally pancreatic cancer (PC) is one of the leading causes of
cancer mortality due to its poor prognosis. While most types of
cancers have seen vast improvements in patient survival within the, 1089, Hungary.
d SK10 3SA, United Kingdom.
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Inc. This is an open access article ulast decade, only about 5% of PC patients survive beyond 5 years of
diagnosis [1,2].
Extracellular vesicles (EVs), nanostructures secreted by most if
not all cells [3,4] have been classiﬁed based on biogenesis and sizes
into different subtypes including exosomes, microvesicles and
apoptotic bodies or large oncosomes [3,5e7]. Since no established
molecular markers for the individual EV subpopulations are avail-
able, here we refer to EV fractions by their size ranges (small, in-
termediate sized and large EVs with 50e150 nm,100e1000 nm and
>1 mm in diameter, respectively) similar to the terms used by the
group of Thery [5]. EVs have been found to carry various molecular
cargoes including proteins [8], RNA [9,10], DNA [11], and lipids [12],nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Morphology, size, and concentration of pancreatic juice and cell line-derived
extracellular vesicles.
Panels A, B, and C, show representative electron microscopic images of large, inter-
mediate, and small extracellular vesicles, respectively, from human pancreatic juice.
Panel D shows representative size distributions of large, intermediate, and small
extracellular vesicles found in human pancreatic juice of patients with chronic
pancreatitis (CP), and adenocarcinomas of the pancreatic head (PH-AC) or hep-
atopancreatic ampulla (A-AC), as well conditioned media of two pancreatic cancer cell
lines (Capan-1, MIA PaCa-2). Panel E shows concentration (Mean± SEM) of large, in-
termediate, and small extracellular vesicles found in pancreatic juices of all patients
while Panel F shows separately those of patients with CP (n¼ 6), and PH-AC, (n¼ 6) or
A-AC, (n¼ 5). Mann Whitney tests revealed statistically signiﬁcant differences when
comparing large to intermediate or small extracellular vesicles across all patients but
no statistically signiﬁcant differences between the patient groups except for patients
with A-AC having signiﬁcantly lower amounts of large EVs as compared to patients
with CP.
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tion, oxidation, citrullination) [13]. By transferring such molecules,
EVs play roles in various processes such as inﬂammation [14],
cancer [8,15,16], and cardiovascular diseases [17,18]. In recent years
EVs have attracted signiﬁcant research interest due to their po-
tential as biomarkers for diseases by carrying molecules from their
releasing cells [19]. Exosome-associated glypican-1 was suggested
as a biomarker for PC [20] while another study showed exosome-
associated miRNA signature to be a superior biomarker of the dis-
ease [21]. Additionally, a nanoplasmonic approach was used for
detection of PC-associated molecules in EVs in as little as 1 mL of
blood plasma [22].
Here we took the approach of characterizing EVs directly in
pancreatic juices (PJ) instead of only in the circulation of PC patients
as previous reports by our group and others have shown that PJ is a
suitable source of EVs [23e26].
Our results show that PJ EVs from various pathologies carry
differential proteomic cargos that may serve for biomarker identi-
ﬁcation and validation.
2. Methods
2.1. Patients and sample collection
Patients with chronic pancreatitis (CP) and adenocarcinomas of
pancreatic head (PH-AC) or hepatopancreatic ampulla (A-AC) were
treated at the 1st Department of Surgery at Semmelweis University.
Supplementary Tables 1 and 2 summarize the data and histological
diagnosis of patients enrolled in this study following the AJCC PC
Staging System [27e29].
When opening of the pancreatic duct was indispensable for
surgery (e.g. partial pancreatic resections, pancreato-
duodenectomies, Vater papilla excisions, pancreatic duct de-
compressions), we punctured it with a cannula (20G) and aspired
1e5mL PJ without appearance of blood. The surgery was then
continued according to routine practices. PJ samples were centri-
fuged twice at 2,500 g for 15min and stored at 80 C until use.
All experimental protocols were approved by the Hungarian
Scientiﬁc and Research Ethics Committee (TUKEB) and performed
in accordance to the guidelines and regulations of the Helsinki
Declaration in 1975. All patients signed an informed consent form.
2.2. Cell lines
Capan-1 andMIA PaCa-2 PC cell lines were provided by Dr. Klaus
Felix, (Universit€at Heidelberg, Heidelberg) and were cultured in
IMDM containing 20% (v/v) fetal bovine serum (FBS) and DMEM
containing 10% (v/v) FBS, respectively. Cell lines were grown with
2mM glutamine and 1% Ab/AM at 37 C in 5% CO2/air, and were
regularly tested for Mycoplasma contamination.
2.3. EV isolation
For cell line-derived EVs, cells were washed three times with
PBS, and EV production took place for 24 h in serum-free medium
to avoid contamination with EVs present in FBS. Viability under
serum free conditions for 24 h was >90e95% as conﬁrmed with
annexin V-FITC and propidium iodide (both from BD Biosciences)
staining as described before [6]. Three size-based EV fractions were
isolated. For cell line-derived EVs, cells were ﬁrst depleted by
centrifugation at 300g for 10min. For PJ-derived EVs, samples were
diluted 4 times in PBS before EV isolation. Next, samples were
ﬁltered by gravity through a 5 mm ﬁlter (Millipore) and centrifuged
at 2,000 g for 10min at room temperature resulting in pellets
enriched in large EVs. Supernatants were next ﬁltered by gravitythrough a 0.8 mm ﬁlter (Millipore) and centrifuged at 12,600 g for
30min at room temperature to result in pellets enriched in inter-
mediate EVs. Finally, supernatants were ultracentrifuged in an
Optima MAX-XP ultracentrifuge with MLA-55 rotor (Beckman
Coulter Inc.) at 100,000 g for 70min at 4 C to result in pellets
enriched in small EVs.
PJ-derived EVs were also isolated by using anti-CD63 magnetic
beads (Thermo Fisher). Brieﬂy, PJ samples were centrifuged at 300 g
for 5min and then 2,000 g 20min. Magnetic beads were blocked by
1% BSA for 30min. Then 12 mL beads/sample were incubated with
250 mL of undiluted PJ supernatant overnight with continuous
rotation at 4 C. This was followed by ﬂow cytometric detection
after staining of bead-bound EVs with ﬂuorescent anti-CD63 PE
(Sigma Aldrich).2.4. Tunable resistive pulse sensing measurements
EVs were analyzed by qNano (IZON Science) as described pre-
viously [6,30,31] with at least 500 particles counts on NP100,
NP400, NP800 and NP2000 nanopores. Events were recorded with
stable current (115e145 nA), root mean square noise below 12 pA,
and linear particle rates using calibration beads CPC100B, CPC400E,
CPC800D and CPC2000D (all from IZON).2.5. Transmission electron microscopy
EV pellets were ﬁxed with 4% paraformaldehyde, washed with
PBS, and post-ﬁxed in 1% OsO4 (Taab) for 30min. After rinsing with
distilled water, pellets were dehydrated in graded ethanol,
including block staining with 1% uranyl-acetate in 50% ethanol for
30min, and were embedded in Taab 812 (Taab). Overnight poly-
merization of samples at 60 C was followed by sectioning and
analysis using a Hitachi 7100 electron microscope (Hitachi Ltd.).
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EVs were incubated with 1 ml of each afﬁnity reagent, antibody
or isotype control (listed in Supplementary Table 3) for 30min at
room temperature in the dark in 50 mL followed by dilution to
300 mL prior tomeasurement. Autoﬂuorescence and ﬂuorescence of
the afﬁnity reagents in the absence of EVs were also determined,
and 0.1% Triton X100 lysis was used as a control to disrupt EV
signals. Isolated small EVs were coupled to 4 mm aldehyde/sulphate
latex beads (Life Technologies), and blocked with 1% bovine serum
albumin in PBS for 2 h followed by 100mM glycine. For
Supplementary Fig. 5A, instrument settings and gates were set as
shown in Supplementary Fig. 1A. For Supplementary Fig. 5B in-
strument settings and gates were set as described earlier [6,30,32]
using Megamix beads (BioCytex) and 1 mm Silica Beads Fluo-Green
(Kisker) as shown in Supplementary Fig. 1B. Data were analyzed
using FlowJo software (Treestar).2.7. Mass spectrometry of EV preparations
EV pellets were re-suspended in 10 mL water and proteins were
extracted using repeated freeze-thaw cycles followed by minia-
turized tryptic digestion as previously described [33]. Peptide di-
gests were analyzed using a Bruker Maxis II Q-TOF (Bremen,
Germany) with CaptiveSpray nanoBooster ionization source. Pep-
tides were separated online using a 25 cmWaters Peptide BEH C18
nanoACQUITY 1.7 mm particle size UPLC column on the Dionex
Ultimate 3000 Nano LC System (Sunnyvale, CA, USA). Trapping was
performed on an Acclaim™ PepMap100™ C18 NanoTrap columnFig. 2. Mass spectrometry of large extracellular vesicles in pancreatic juice and blood plasm
Panel A shows shared and unique proteins found in large extracellular vesicles from pancrea
pancreatic head (PH-AC) or hepatopancreatic ampulla (A-AC). Panel B shows cellular compo
each patient group. Panel C shows shared and unique proteins in large extracellular vesicles f
some of the unique and common proteins as well as those expected to be present in extracel
patient groups.(5 mm, 100 Å, 100 mm 20mm, Thermo Fisher). Data were evalu-
ated with Funrich [34] and Scaffold 4.5.3 (http://www.
proteomesoftware.com), using Mascot (Matrix Science, London,
UK; version Mascot 2.5) and X!Tandem (The GPM, thegpm.org;
version 2007.01.01.1) search engines. Protein identiﬁcation criteria
against Swissprot (2015_08) database was in accordance to strict
criteria of Molecular and Cellular Proteomics guidelines. Brieﬂy,
7 ppm peptide mass tolerance, 0.05 Da fragment mass tolerance
and 2 missed cleavages were allowed and the following modiﬁca-
tions were searched: carbamidomethylation as ﬁxed modiﬁcation,
while deamidation (NQ), oxidation (M) and pyro-
carbamidomethylation (N-term C) as variable modiﬁcations.
2.8. Protein and lipid determination of EV preparations
Protein content of EVs was determined using the Micro BCA Pro-
tein Assay Reagent Kit (Thermo Fisher), and lipid content was deter-
minedwith the sulfophosphovanilin reaction as described earlier [6].
2.9. Statistical analysis
Data were analyzed with GraphPad Prism v.4 using unpaired t-
test for parameters with normal distribution and Mann Whitney
test for parameters with non-normal distribution. P values lower
than 0.05 were considered statistically signiﬁcant.
2.10. Data availability
MS datasets are available from the publication date on EVpediaa.
tic juice samples of patients with chronic pancreatitis (CP), and adenocarcinomas of the
nent analysis of proteins found in large extracellular vesicles from pancreatic juices of
rom blood plasma of the above patient groups as well as healthy donors. Panel D shows
lular vesicle isolates were found in large extracellular vesicles in pancreatic juices of the
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), and Exocarta (http://www.exocarta.org/). All other data gener-
ated or analyzed during this study are included in this published
article (and its Supplementary Information ﬁles).3. Results
3.1. Human pancreatic juice samples contain extracellular vesicles
Human PJ samples were obtained by intraoperative punctures of
patients with CP, PH-AC, or A-AC. PJ-derived small, intermediate,
and large EVs were analyzed by TEM showing characteristic
phospholipid bilayer-enclosed EV structures in all pellets
(Fig. 1AeC). Furthermore, EV pellets of conditioned media of
Capan-1 cells showed similar structures (Supplementary Fig. 2).
Protein to lipid ratios of PJ EVs were found within the expected
ranges for typical EV preparations with values of 0.41± 0.09,
0.30± 0.06, and 0.37± 0.07 (Mean± SEM) for large, intermediate,
and small EVs respectively (Supplementary Fig. 3).3.2. Size and concentration of EVs in human pancreatic juice
samples
PJ samples from CP (n¼ 6), PH-AC (n¼ 6), and A-AC (n¼ 5)
patients were submitted to TRPS-based size and concentration
determination. Fig. 1D shows representative particle sizeFig. 3. Mass spectrometry of intermediate extracellular vesicles in pancreatic juice and blo
Panel A shows shared and unique proteins found in intermediate extracellular vesicles from
nomas of the pancreatic head (PH-AC) or hepatopancreatic ampulla (A-AC). Panel B shows ce
pancreatic juices of each patient group. Panel C shows shared and unique proteins in interm
healthy donors. Panel D shows some of the unique and common proteins as well as thos
extracellular vesicles in pancreatic juices of the patient groups.distributions. PJs had EVs with diameter sizes of 1646.0± 41.5 nm,
189.8± 11.41 nm, and 125.4± 3.8 nm (Mean± SEM) for large, in-
termediate, and small EVs respectively. While the diameter sizes of
PJ and PC cell line derived EVs were similar, PJ had higher con-
centrations of small and intermediate but not large EVs (Fig. 1D).
TRPS showed that small EVs were more abundant in PJ samples
than intermediate and large ones across all patient groups with
mean concentrations of 6.1± 2.2 106, 1.7± 0.5 1010, and
2.9± 0.6 1010 particles/mL (Mean± SEM) for large, intermediate,
and small EVs respectively (Fig. 1E). However, patient groups did
not signiﬁcantly differ in concentrations of small and intermediate
sized EVs, but patients with A-AC had signiﬁcantly lower amounts
of large EVs as compared to patients with CP with mean concen-
trations of 2.0± 0.9 106 particles/mL compared to of
1.1± 0.6 107 particles/mL (Mean± SEM) (Fig. 1F).3.3. Mass spectrometry of EVs
Mass spectrometry of EV pellets from PJ, conditioned media of
PC cell lines, and blood plasma samples identiﬁed high number of
proteins with at least two peptides in EV fractions isolated from
each source (Supplementary Table 4). MS data from PJ-derived EVs
showed relative enrichment with proteins expressed in pancreas as
compared to blood or bile ﬂuid (Supplementary Fig. 4).
Next, we compared the identiﬁed proteins in EV pellets among
patients with CP, PH-AC, and A-AC (n¼ 4 in each group). Fig. 2A andod plasma.
pancreatic juice samples of patients with chronic pancreatitis (CP), and adenocarci-
llular component analysis of proteins found in intermediate extracellular vesicles from
ediate extracellular vesicles from blood plasma of the above patient groups as well as
e expected to be present in extracellular vesicle isolates were found in intermediate
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large EVs from PJ (A) and blood plasma (C) for each disease group.
Fig. 2B shows cellular component Gene Ontology (GO) annotation
of proteins identiﬁed in large EVs from PJ with most proteins
belonging to the “extracellular exosome” GO category. Fig. 2D
shows candidate markers found in PJs including those i) detected
uniquely in each patient group, ii) commonly in both adenocarci-
nomas, iii) in all large EVs, and iv) considered typical proteins ex-
pected in EV isolates [35]. Bold letters show proteins also identiﬁed
in EVs of PC cell lines. Italics show proteins found in blood plasma
as well. Figs. 3 and 4 show results obtained with intermediate and
small EVs pellets, respectively.3.4. Flow cytometric detection of the candidate pancreatic cancer
proteins associated with EVs
We used ﬂow cytometry for detection of candidate markers in
EVs isolated from PJs and conditioned media of PC cell lines.
Supplementary Fig. 5A shows PJ EVs stained with ﬂuorescent an-
tibodies to known EV proteins as well as proteins identiﬁed by MS
of PJ EV isolates. PJ EVs showed positivity for CD63, CD81, CD107a
(LAMP-1), MUC5AC, CFTR, and TO-PRO3 DNA binding dye.
Supplementary Fig. 5B shows detection of MUC1, MUC4, MUC5AC,
CFTR, and MDR1, as well as annexin V on EVs isolated from PC cell
lines. While some differences were observed in staining intensities,
all markers were present in EV fractions secreted by the tested PC
cell lines. Supplementary Fig. 5C demonstrates PJ EVsFig. 4. Mass spectrometry of small extracellular vesicles in pancreatic juice and blood plas
Panel A shows shared and unique proteins found in small extracellular vesicles from pancrea
pancreatic head (PH-AC) or hepatopancreatic ampulla (A-AC). Panel B shows cellular compo
each patient group. Panel C shows shared and unique proteins in small extracellular vesicles f
some of the unique and common proteins as well as those expected to be present in extracell
patient groups.immunocaptured using magnetic beads showing positivity for the
membrane tetraspanin CD63.4. Discussion
PC remains a malignancy with an outstandingly high mortality
rate and EVs have been suggested to represent a promising source
of circulating markers for tumors like PC. In this study and earlier
reports from our group [25,26], we have shown for the ﬁrst time
that EVs are present in human PJ samples. This ﬁnding allowed for a
novel approach whereby EVs were directly analyzed from PJs of
cancer patients.
The presence of EVs in the enzyme-richmilieu of PJ is somewhat
unexpected. Multiple evidence for the existence of EVs in PJ sam-
ples are presented in this study. These include i) electron micro-
photographs (Fig. 1AeC), ii) particle detection in typical EV size
ranges by TRPS (Fig. 1DeF), iii) enrichment of proteins in EVs iso-
lates corresponding to the “extracellular exosome” GO category
including typical proteins expected in EV isolates [35] (Figs. 2e4, iv)
detection of EV markers (CD63, CD81 and LAMP-1) on PJ EVs by
ﬂow cytometry (Supplementary Fig. 5A) and v) demonstration of
the presence of CD63 positive EVs captured by immunoafﬁnity on
magnetic beads (Supplementary Fig. 5C).
This study differed from previous ones where EV biomarkers
were searched either from conditioned media of PC cells or from
the circulation, where the vast majority of EVs are of non-tumor
origin [19e22]. Another original aspect of this study was analysisma.
tic juice samples of patients with chronic pancreatitis (CP), and adenocarcinomas of the
nent analysis of proteins found in small extracellular vesicles from pancreatic juices of
rom blood plasma of the above patient groups as well as healthy donors. Panel D shows
ular vesicle isolates were found in small extracellular vesicles in pancreatic juices of the
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our laboratory and others showing that size-based EV fractions
differ in nucleic acid [10], protein [5], and lipid properties [6].
Our proteomic analysis revealed that 41.8%, 48.4% and 50.1% of
the identiﬁed proteins were unique to the different size-based EV
fractions of patients with CP, PH-AC and A-AC, respectively. These
data conﬁrm that a speciﬁc EV fraction may carry markers not
present in other fractions. More importantly, we found unique
proteins for each patient group in the EV fractions. These included
Mucin-4, Mucin-5AC, Mucin-6, and Mucin-16, detected exclusively
in PJ EVs of PH-AC patients in accordance with the long known
association of mucins with PC [36]. Other characteristic PH-AC
proteins included HSP 90 alpha, cystic ﬁbrosis transmembrane
conductance regulator (CFTR) and multidrug resistance protein 1
(MDR1). MDR1 was shown earlier in association with prostate
cancer-derived EVs [37]. Furthermore, CFTR has been found in as-
sociation with EVs [38] and it has also been implicated in the
pathomechanism of PC with mutations increasing the risk for this
malignancy [39]. Importantly, we validated the presence of some of
these proteins by ﬂow cytometry on PC cell line-derived and PJ-
derived EVs.
While this and other studies [20e22,24e26,40] provide some
molecular candidates for diagnosis of PC, there is need for further
validation with greater number of patient samples before EV di-
agnostics become a reality in the clinic. Nevertheless, in this study
we provide evidence that PJ is a bioﬂuid in which EVs are present
and can be isolated to serve as potential sources of biomarkers for
PC.
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